Will Increased Awareness Among Physicians of the Significance of Sudden Agonizing Headache Affect the Outcome of Subarachnoid Hemorrhage?

Abstract

We have established our population as valid historical controls and outlined our campaign strategy. Lowering the clinical threshold at which patients with sudden agonizing headache are screened for aneurysms or arteriovenous malformations will undoubtedly increase diagnostic costs. However, for reasons given in the text, we estimated the cost per quality-adjusted life year gain to be 1000 pounds ($1500).